Dihydromyricetin promotes hepatocellular carcinoma regression via a p53 activation-dependent mechanism

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Zhang, Qingyu ^a   Liu, Jie ^a   Liu, Bin ^a   Xia, Juan ^a   Chen, Nianping ^a   Chen, Xiaofeng ^a   Cao, Yi ^b   Zhang, Chen ^b   Lu, Caijie ^a   Li, Mingyi ^a   Zhu, Runzhi ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b KUNMING INSTITUTE OF ZOOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMPELOPSIN; ANTINEOPLASTIC AGENT; CISPLATIN; FLAVONOL DERIVATIVE; PROTEIN P53; SMALL INTERFERING RNA;

ANIMAL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL PROLIFERATION; CHINESE MEDICINE; CYTOLOGY; DRUG EFFECT; DRUG SCREENING; ENZYME ACTIVATION; HEPG2 CELL LINE; HUMAN; LIVER; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; ENZYME ACTIVATION; FLAVONOLS; HEP G2 CELLS; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MEDICINE, CHINESE TRADITIONAL; MICE; MICE, INBRED BALB C; MICE, NUDE; PHOSPHORYLATION; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84898476245     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep04628     Document Type: Article

References (27)

1. Feng, M. et al. Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. P Natl Acad Sci USA 110, E1083-E1091(2013).
2. Wilson, T. R. et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505-509 (2012).
3. Meyskens, F. L. & Gerner, E. W. Development of Difluoromethylornithine (DFMO) as a Chemoprevention Agent. Clin Cancer Res 5, 945-951 (1999). (Pubitemid 29233206)
4. Suzuki, R. et al. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. Int J Pharm 346, 143-150 (2008). (Pubitemid 350101994)
5. Florea, A.-M. & Büsselberg, D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers 3, 1351-1371 (2011).
6. Xu,W., Towers, A., Li, P.& COLLET, J. P. Traditional Chinese medicine in cancer care: perspectives and experiences of patients and professionals in China. Euro J Cancer Care 15, 397-403 (2006). (Pubitemid 44359404)
7. Zhang, X. W. et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 328, 240-243 (2010).
8. Amin, A. R., Kucuk, O., Khuri, F. R. & Shin, D. M. Perspectives for cancer prevention with natural compounds. J Clin Oncol 27, 2712-2725 (2009).
9. Gullett, N. P. et al. Cancer prevention with natural compounds. Semin Oncol 37, 258-281 (2010).
10. Tsuda, H. et al. Cancer prevention by natural compounds. Drug Metab Pharmacok 19, 245-263 (2004).
11. Nazemiyeh, H. et al. Antioxidant phenolic compounds from the leaves of Erica Arborea (Ericaceae). Nat Prod Res 22, (2008).
12. Shen, Y. et al. Dihydromyricetin as a novel anti-alcohol intoxication medication. J Neurosci 32, 390-401 (2012).
13. Shukla, Y. & Singh, M. Cancer preventive properties of ginger: a brief review. Food Chem Toxicol 45, 683-690 (2007). (Pubitemid 46452881)
14. Wu, S. et al. Dihydromyricetin Reduced Bcl-2 Expression via p53 in Human Hepatoma HepG2 Cells. PloS One 8, e76886 (2013).
15. Vara, J.Á . F. et al. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30, 193-204 (2004).
16. Cardone, M. H. et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 282, 1318-1321 (1998). (Pubitemid 28524494)
17. Li, W., Zheng, H., Bukuru, J. & De Kimpe, N. Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus. J Ethnopharmacol 92, 1-21 (2004). (Pubitemid 38510258)
18. Langmead, L. & Rampton, D. Review article: herbal treatment in gastrointestinal and liver disease-benefits and dangers. Aliment Pharm Therap 15, 1239-1252 (2001). (Pubitemid 32835530)
19. Ji, H.-F., Li, X.-J.& Zhang, H.-Y.Natural products and drug discovery. EMBO Rep 10, 194-200 (2009).
20. Vara, J.Á . F. et al. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30, 193-204 (2004).
21. Hennessy, B. T., Smith,D. L., Ram, P. T., Lu, Y. &Mills, G. B. Exploiting the PI3K/ AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4, 988-1004 (2005).
22. del Peso, L., Gonzalez-Garcia, M., Page, C.,Herrera, R.&Nunez, G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278, 687-689 (1997). (Pubitemid 27464966)
23. Bailey, S. M. et al.DNAdouble-strand break repair proteins are required to cap the ends ofmammalian chromosomes. P Natl Acad Sci USA 96, 14899-14904 (1999). (Pubitemid 30019737)
24. Rubbi, C. P. & Milner, J. p53 is a chromatin accessibility factor for nucleotide excision repair of DNA damage. EMBO J 22, 975-986 (2003). (Pubitemid 36227799)
25. Michael, D. & Oren,M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 13, 49-58 (2003). (Pubitemid 36269180)
26. Moll, U. M. & Petrenko, O. The MDM2-p53 interaction. Mol Cancer Res 1, 1001-1008 (2003). (Pubitemid 38044975)
27. Banin, S. et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281, 1674-1677 (1998).